Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Prato

65 clinical trials in Prato, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Prato at a glance
65
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

65 trials in Prato

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Fallopian tube cancer+2

Recruiting

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Desmoplastic small round cell tumour

Recruiting

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin
  • Sponsor:Italian Sarcoma Group

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Prato

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including innovative therapies and maintenance strategies.

  • Advanced treatment combinations
  • Hormone therapy optimization
  • Targeted therapies

Multiple studies evaluating novel drug combinations and personalized treatment approaches for various breast cancer subtypes.

02 Gastrointestinal Oncology

Innovative research in colorectal cancer and pancreatic cancer, exploring new treatment combinations and maintenance therapies.

  • First-line treatments
  • Maintenance strategies
  • Targeted therapeutic approaches

Studies focus on improving survival rates and treatment effectiveness for advanced gastrointestinal cancers.

03 Gynecologic Oncology

Research targeting ovarian cancer and related conditions, with emphasis on platinum-sensitive diseases and novel therapeutic combinations.

  • Maintenance treatments
  • Combination therapies
  • Treatment optimization

Trials exploring new approaches for treating various types of gynecologic cancers with innovative drug combinations.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.